Recent Quotes (30 days)

You have no recent quotes
chg | %

Med Biogene Inc  

(Public, CVE:MBI)   Watch this stock  
Find more results for MBI
0.0000 (0.00%)
Nov 25 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.05 - 0.05
52 week 0.03 - 0.10
Open 0.05
Vol / Avg. 25,000.00/19,912.00
Mkt cap 3.88M
P/E     -
Div/yield     -
EPS -0.01
Shares 86.58M
Beta 2.33
Inst. own     -

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -535.06% -174.17%
Return on average equity -1733.95% -784.28%
CDP Score - -


598 East Kent Avenue South
+1-604-7328821 (Phone)
+1-604-7324801 (Fax)

Website links


Med BioGene Inc. (MBI) is a Canada-based life science company. The Company is focused on the development and commercialization of genomic-based clinical laboratory diagnostic tests. The Company is also focused on managing the license and rights to GeneFx Lung, a prognostic genomic-based test for non-small-cell lung cancer (NSCLC). The Company markets various tests through its Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory, including ChemoFx, BioSpeciFx, iRview mets2 and GeneFx Colon. Both GeneFx Colon and GeneFx Lung are gene expression-based tests and, accordingly, share the brand name GeneFx. Early-stage NSCLC patients are treated primarily by surgical removal of their tumors. Recent clinical trials have shown that adjuvant chemotherapy, administered after tumor removal improves the survival of stage II patient.

Officers and directors

Iain Weir-Jones Ph.D. Chairman of the Board, Chief Executive Officer
Ibrahim Ghobrial Chief Financial Officer
Devid Diebolt Director
Terence W. Friedlander Director
Shumsheer Sidhu Director
Toby Weir-Jones Director